Polypeptide With Localisation/Targeting Motif TRIZ Cases

Segmenting antigen recognition into modular synNotch switches resolves the trade-off between targeting specificity and circuit complexity.

Anti-HER2 antigen-binding proteins enable CAR-T cells to overcome drug resistance in HER2-positive tumors.

Engineered extracellular vesicles deliver antigens to the central nervous system.

Combines an IL-2 fusion protein with angiogenesis inhibitors to activate CD8+ T cells while blocking tumor vascular growth pathways.

Multiple guide RNAs target BCL11a enhancers to increase fetal hemoglobin levels, resolving low editing efficacy in quiescent cells.

Dimeric antigen receptors improve tumor eradication and T cell persistence by integrating costimulatory domains into a single signaling unit.

Ribonucleoprotein editing of TGFBR2 in T cells boosts granzyme B expression and lysis activity against solid tumors without systemic autoimmune phenotypes.

Engineered myeloid cells overcome immunosuppressive microenvironments and improve anti-tumor efficacy.

Dual-receptor logic gates activate cytotoxicity only upon binding ICOS and IL-1R1, depleting immunosuppressive Tregs while sparing circulating populations.

Segmented docking sequences target c-Fos phosphorylation, resolving toxicity trade-offs in Ras/ERK pathway inhibition.

Genetically modified T cells target colony stimulating factor 1 receptor on acute myeloid leukemia cells to reduce toxicity from healthy cell damage.

Self-delivering profiling peptides measure Mcl-1 dependency percentages without digitonin permeabilization, enabling accurate cancer sensitivity assays.

Overexpressing CDC42 in modified T cells boosts cytokine release and migration, addressing solid tumor targeting limitations.

Wiskott-Aldrich locus promoter regulates chimeric antigen receptor expression to mitigate cytokine release syndrome severity and extend T cell longevity.

Segmented CAR constructs enable specific killing of CD38+ malignancies while protecting normal hematopoietic progenitor cells from toxicity.

NIR-Fbs stabilize and fluoresce upon antigen binding, reducing background noise from unbound nanobodies.

A pharmaceutical composition combines viral antigens with a TLR-3 agonist to induce immediate innate and long-term adaptive immune responses.

Segmented polypeptide spacers amplify signal brightness while minimizing background staining for rare CAR cell quantification.

STEAP2-directed CAR-T cells specifically target and kill tumor cells expressing the STEAP2 antigen.

Segmented chimeric antigen receptor constructs utilize optimized extracellular binding domains to enhance specificity and efficacy against solid tumor cells.

Pro-IL-1α peptide reduces tumor burden by suppressing Akt1 activation and glycolysis, addressing ineffective metastatic treatments.

A segmented peptide uses enzyme cleavage to release masking domains, enabling targeted drug delivery while minimizing systemic side effects.

Fusion peptides merge membrane penetration domains with target binding modules to overcome cellular uptake barriers and inhibit bacterial replication.

Chimeric antigen receptors direct engineered T cells to destroy mesothelin-positive cancers while reducing systemic toxicity.

Bispecific chimeric antigen receptors bind simultaneously to BCMA and CD307e, preventing tumor escape from single-antigen loss.

Intermediate affinity CAR designs reduce cytokine release syndrome while maintaining tumor cytotoxicity and immune cell persistence.

A hybrid signal sequence fusing alpha-mating factor and Srh1 hydrophobin segments enhances human insulin-like growth factor-1 secretion in Komagataella phaffii.

Codon optimization and signal peptide secretion of Der p1 in Pichia pastoris resolve contamination risks from crude extracts.

CRISPR deletion of TRAC and TRBC genes removes graft-versus-host disease risk while lymphodepletion enhances persistence in relapsed patients.

Disarmed Agrobacterium strains with VirD2 variants bypass tissue culture selection, enabling efficient chloroplast transformation in seed plants.

RGNEF leucine-rich domain expression reduces TDP-43-induced cytotoxicity and extends lifespan in ALS models.

Segmented adjuvant systems stimulate targeted Th1 and Th2 pathways to reduce viral load and histopathological scores without antibiotic reliance.

Turn-on dioxetane probes emit light upon protease cleavage for live cell imaging.

Segmenting the protocol into pre-activation, expansion, and enrichment phases resolves the contradiction between high CD8+ yield and process complexity.

A multimeric fusion protein carries sialyltransferase and galactosyltransferase domains to modify IgG glycosylation patterns.

Modified antigen binding polypeptides improve alpha/beta TCR/CD3 complex binding through targeted amino acid substitutions.

Lpp mutations enable E. coli to secrete heterologous proteins directly into fermentation media.

Replacing native signal peptides with heterologous amylase sequences resolves secretion bottlenecks and increases enzyme yield.

Modulating intracellular signaling domains in subset-optimized CAR T cells resolves the contradiction between cell persistence and anti-tumor activity.

PTD-SUMO fusion proteins deliver reprogramming factors into cells via membrane transduction, avoiding viral integration risks and genomic instability.

Amino acid substitutions in the SpCas9 PAM recognition domain expand targetable genomic sites by accepting non-canonical PAMs like NGN and NNG.

Targeting intracellular Bob1 peptides via HLA-B*35:01 overcomes extracellular antigen loss in B cell malignancies.

Co-expressing CXCR2 with a GPC3-targeting STAR receptor overcomes limited solid tumor infiltration by improving T cell migration and killing efficacy.

Inducible promoter systems regulate CAR expression via doxycycline, resolving toxicity from uncontrolled proliferation while maintaining anti-tumor activity.